EM49, a new peptide antibiotic. 3. biological characterization in vitro and in vivo.
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005227:Fatty Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012440:Saccharomyces / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes / Q000187:drug effects; D014244:Trichomonas / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D005227:Fatty Acids; D010456:Peptides, Cyclic